Author:
Mbagwu JP. C.,Olajugba J. O.,James-Okoro Paula-Peace,Blessing Obidike
Abstract
Abstract
Background
The majority of COVID-19 research has been devoted to characterizing the epidemiology and early clinical aspects of the virus. In Lagos, Nigeria, we looked at the temporal progression of COVID-19 patients. We included 1337 confirmed COVID-19 cases in our study from February 27th to March 27th 2020. Of the 1337 patients enrolled, the median age was 50 years old, and 800 (59.83%) were male while 537 (40.16%) were female.
Method
In symptomatic patients, the time from the beginning of signs to admission was 4 (2–7) days. Fever occurred in 217 (16.2%) while cough occurred in 211(15.78%) patients respectively. Patients were given 5–6 treatment, including nutrition support, supplementary oxygen, and antiviral medicines (e.g., Remdesivir, dexamethasone) in a limited percentage of cases. The assessed median period of infection in all patients was 10 days after the start of symptoms (95 confidential intervals [CIs]: 8–11 days). The duration of fever was slightly longer in patients admitted to intensive care units (ICU) than in those who were not (31 days versus 9 days, respectively, P < 0.003).
Results
On day 7 after the onset of symptoms, radiological deterioration of the original picture was found in 500 (37.39%) patients. On day 13, 154 of these patients (94.5%) showed signs of radiological improvement. The average time it took for upper respiratory tract samples to test negative for reverse transcriptase PCR was 10 days (90 percent confidence interval: 10–12 days). Virus clearance was more significant in ICU patients than in non-ICU patients (P < 0.003).
Conclusions
Community members should continue to adhere to the recommended methods of preventing the spread of COVID-19 infection and patients should seek care early to reduce the risk of mortality associated with the infection as rapidly as possible.
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: The mystery and the miracle. J Mol Virol. 2020;92:401–2.
2. Wang Y, Huang C, Li Z, Ren I, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel corona virus in Wuhan China. Lancet. 2020;395:497–506.
3. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Guan W, Sang L, Lu J. Development and validation of clinical risk score to predict the occurrence critical illness in hospitalized patient with COVID-19. JAMA Intern Med. 2020;180:1–5.
4. Shrikushna SU, Quazi BA, Shubham S, Suraj T, Shreya W, Rohit B, Suraj S, Biyami KR. A review on Corona Virus (Covid-19). World Journal of Pharmaceutical and Life Sciences. 2020;6(4):109–15.
5. World Health Organization, Emergencies, Preparedness, Response. Pneumonia of unknown origin-China. 2020. Disease Outbreak News. 5 Available from” https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/. (Accessed 22 May 2021).